Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis, Japanese Encephalitis Virus Disease
Trial Timeline
Jul 1, 2011 → Jun 1, 2013
NCT ID
NCT01396512About Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine) is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01396512. Target conditions include Japanese Encephalitis, Japanese Encephalitis Virus Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01396512 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis